KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Non-Current Deffered Revenue (2017 - 2025)

Historic Non-Current Deffered Revenue for Bionano Genomics (BNGO) over the last 9 years, with Q3 2025 value amounting to $192000.0.

  • Bionano Genomics' Non-Current Deffered Revenue fell 2699.62% to $192000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $192000.0, marking a year-over-year decrease of 2699.62%. This contributed to the annual value of $267000.0 for FY2024, which is 7337.66% up from last year.
  • Per Bionano Genomics' latest filing, its Non-Current Deffered Revenue stood at $192000.0 for Q3 2025, which was down 2699.62% from $243000.0 recorded in Q2 2025.
  • Over the past 5 years, Bionano Genomics' Non-Current Deffered Revenue peaked at $292000.0 during Q1 2025, and registered a low of $108000.0 during Q1 2021.
  • Over the past 5 years, Bionano Genomics' median Non-Current Deffered Revenue value was $186000.0 (recorded in 2023), while the average stood at $188210.5.
  • As far as peak fluctuations go, Bionano Genomics' Non-Current Deffered Revenue surged by 15357.14% in 2021, and later tumbled by 2886.6% in 2024.
  • Quarter analysis of 5 years shows Bionano Genomics' Non-Current Deffered Revenue stood at $146000.0 in 2021, then fell by 13.01% to $127000.0 in 2022, then grew by 21.26% to $154000.0 in 2023, then surged by 73.38% to $267000.0 in 2024, then fell by 28.09% to $192000.0 in 2025.
  • Its Non-Current Deffered Revenue was $192000.0 in Q3 2025, compared to $243000.0 in Q2 2025 and $292000.0 in Q1 2025.